Cholangiocarcinoma News

Hot Topics on Cholangiocarcinoma at the 2023 Cholangiocarcinoma Foundation Annual Conference

CCF Highlights
Videos — April 11, 2023

Featuring:

Melinda Bachini
Director of Advocacy
Cholangiocarcinoma Foundation
Billings, MT
Juan W. Valle, MB ChB, MSc, FRCP
Professor and Honorary Consultant
Medical Oncology
Manchester Academic Health Sciences
Centre Institute of Cancer Studies
University of Manchester
Lead, The Christie European
Neuroendocrine Tumour Society
Centre of Excellence
Manchester, UK

On April 14, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 Cholangiocarcinoma Foundation Annual Conference. In addition, we provided our perspectives on the impact of the data on the management of patients with CCA.

Related Items

Importance of Proper Nutrition in Patients With Cholangiocarcinoma
CCF Highlights
June 2023, Vol 4, No 2
A specialist in oncology nutrition and the caregiver of a patient with cholangiocarcinoma discuss the importance of proper nutrition in achieving positive cancer outcomes.
Read More
Physician Debate: Is Chemotherapy Still the Backbone for CCA Treatment?
CCF Highlights
June 2023, Vol 4, No 2
Dr Rachna Shroff and Dr Madhulika Eluri debated whether it is time to move away from chemotherapy as a mainstay in the treatment of cholangiocarcinoma.
Read More
Incorporating ctDNA Into Clinical Trial Design
CCF Highlights
June 2023, Vol 4, No 2
Cholangiocarcinoma experts discussed potential applications of liquid biopsies using circulating tumor DNA.
Read More
Harnessing the Microbiome to Optimize Response to Immunotherapy
CCF Highlights
June 2023, Vol 4, No 2
Dr Marina Barcena-Varela described a study that aims to understand how the microbiome affects cholangiocarcinoma tumorigenesis based on genetic alterations and response to targeted and immunotherapy.
Read More
New Treatment Strategy for FGFR2 Fusion–Positive CCA
CCF Highlights
June 2023, Vol 4, No 2
Dr Michael E. Lidsky described a novel investigative murine model of FGFR2 fusion–positive intrahepatic cholangiocarcinoma and how it may enhance treatment outcomes.
Read More
CDX-1140 Plus Capecitabine, Oxaliplatin, and Pembrolizumab in Advanced BTC
CCF Highlights
June 2023, Vol 4, No 2
Dr Cecilia Monge presented the rationale and study design for a new phase 2 study investigating the CD40 agonist CDX-1140 in combination with capecitabine, oxaliplatin, and pembrolizumab in advanced biliary tract cancer.
Read More
Emerging Therapeutic Targets for CCA From Translational Research
CCF Highlights
June 2023, Vol 4, No 2
Dr Tim F. Greten discussed emerging targets for the treatment of cholangiocarcinoma coming from translational research studies.
Read More
Advances in CAR T-Cell Therapy in CCA
CCF Highlights
June 2023, Vol 4, No 2
Dr Mark O’Hara discussed the growing potential of CAR T-cell therapy in cholangiocarcinoma.
Read More
The Future of Clinical Trial Design in CCA Informed by Past Experiences
CCF Highlights
June 2023, Vol 4, No 2
Dr Sandra J. Casak discussed future thinking regarding clinical trials in cholangiocarcinoma, including a “seamless” oncology drug development paradigm.
Read More
CCA Summit Live from ESMO 2022
By Juan W. Valle, MB ChB, MSc, FRCP
ESMO Highlights
Videos
On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.
Read More

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly CCA News print publication and CCA News weekly e‑newsletter.

© Amplity Health. All Rights Reserved. Privacy Policy.